Objective: Adverse effects (AEs) of antipsychotic medication have important implications for patients and prescribers in terms of well-being, treatment adherence, and quality of life. This review summarizes strategies for collecting and reporting AE data across a representative literature sample to ascertain their rigor and comprehensiveness.
A ntipsychotic medication is associated with numerous adverse effects (AEs), ranging from mild and intermittent (eg, dizziness and nausea) to incapacitating (eg, extrapyramidal symptoms [EPS]), some of which can disrupt an array of physical and psychological systems. [1] [2] [3] Since the introduction of antipsychotics in the 1950s, it has been recognized that patients generate subjective interpretations of the sensations that attend drug consumption. However, the imperative for standardizing psychiatric phenomena arguably led "to a gradual disregard of subjective experiences… which were relegated to "soft science" (Awad et al, p.55) . 4 Correspondingly, much research has prioritized efficacy and safety parameters rather than the more subjective construct of tolerability. Interest in the latter was advanced by the work of Hogan et al 5 whose scale for assessing antipsychotic responses indicated that "maximum variability…is accounted for by items reflecting how the patient feels on medication, rather than what he knows or believes about medication" (p.177). In this respect, patient testimony indicates that AEs are sometimes experienced as equally 6 or more 7 distressing than the symptoms targeted by the drugs.
The realization that AEs have implications for treatment adherence, 8 quality of life, 9 mortality, 10 suicidal ideation, 11 and litigation suits 12 means greater attention is being paid to phenomenological aspects of antipsychotic use. The development of psychometrically robust scales that patients can reliably complete has also advanced the research agenda. [13] [14] [15] This is important progress, given the necessity of auditing the relative prevalence and severity of AEs, and the corresponding impact on patient well-being. In this respect, the substantial differences in AE profiles for different antipsychotics (compared with robust, yet small, mean differences in efficacy) 16 makes the former an important component of prescribing choices and, in accordance with best-practice guidelines, can empower service users in making informed treatment decisions 17 about the short-and long-term risk/benefit ratios.
Despite the utility of assessing and documenting AEs, recording is frequently deficient. [18] [19] [20] For example, an analysis of 182 randomized trials for assorted psychiatric interventions reported that 58.3% assigned more page space to authors' names and affiliations than safety statistics. 21 A review of safety and tolerability data from 167 antipsychotic trials likewise indicated numerous failings, primarily inconsistent measurement, and inadequate or confusing reporting. 22 Other authors have provided detailed information on global AE domains (eg, EPS 23 ), specific experiences (eg, hyperprolactinemia 24 ), or the safety and tolerability profiles for particular classes (eg, long-acting injections 25 ) or brands 26 of drug. However, there is currently a lack of comprehensive information about the methods used for assessing adverse antipsychotic effects across the broader evidence base (including, but not limited to, clinical trials), the types of effects being reported, and whether screening procedures differ according to the effects being assessed.
Aims of the Study
The aim of the current review was 2-fold: (1) to summarize strategies used across a representative literature sample for obtaining and reporting data on the adverse effects of antipsychotic medication and (2) to ascertain the comprehensiveness and methodological rigor of these strategies. As our approach was an exploratory one, we had no prespecified hypotheses.
MATERIALS AND METHODS

Search Procedure
The search, extraction, and data synthesis process were informed by preferred reporting items for systematic reviews and meta-analyses statement guidelines. 27 Articles were searched for using the PsycINFO database (OVID interface) and used the following search string: (antipsychotic* or neuroleptic*) and (subjective effect or subjective experience or subjective response or subjective mental alterations or subjective tolerability or subjective well-being or patient perspective or self-rated effects or adverse effects or side effects). This strategy resulted in 7825 titles and abstracts.
Inclusion Criteria
Studies were sought that appeared in peer-reviewed Englishlanguage journals from 1980 to July 2014 and reported quantified results for AEs of typical or atypical antipsychotics among transdiagnostic adult, adolescent, and child populations.
Exclusion Criteria
Case studies/series, review articles, and conference proceedings were not retained. Also excluded were studies evaluating psychotropic medication without reporting specific findings for antipsychotics; studies only providing laboratory safety data; studies on healthy volunteers or nonpsychiatric patient populations; studies reporting patient attitudes toward, beliefs about, and/or general well-being in relation to antipsychotic therapy without describing specific AE outcomes; studies reporting a single aspect (eg, amenorrhea only) or domain (eg, EPS only) of AEs; reports of augmenting antipsychotics with agents for controlling EPS; studies evaluating adjunctive therapies for antipsychotics as a primary outcome measure; studies evaluating unmarketed or discontinued compounds. Studies only reporting a single global score from assessment instruments were also excluded because it was not possible to code such studies according to separate AE domains.
Data Extraction
Information extracted from source papers included: date, research design, clinical population, participants' mean age, and whether medication dosage and polypharmacy was reported. For clinical studies, data were extracted on whether the number of participants withdrawing due to AEs was reported, and if so, whether the type(s) of effect leading to discontinuation were identified.
To derive a global score for the comprehensiveness of AE reporting in each study, the following information was extracted and coded as primary outcomes of interest:
Adverse Effect Assessment
For the purposes of the review, AEs were defined as secondary effects that are generally unwanted, are distinct from the medication's therapeutic effect, are not necessary for its desired action, and can be experienced and identified by patients independent of laboratory or clinical testing. 28, 29 Because the review was concerned with known effects of antipsychotics at normal doses, data on adverse drug events were not retained (eg, overdose, instances of prescribing/dispensing malpractice).
Coding was organized according to the AE categories outlined in Table 1 . For each domain, studies were coded 0 if no attempt was made to assess these effects, or if they were assessed but not reported. Assessment based on spontaneous self-report, observational monitoring, or unspecified checklists were coded as 1. Studies scored 2 if effects had been assessed using validated self-report inventories or structured clinical interviews. Metabolic effects were also coded as 2 if investigators provided numericized results pertaining to weight gain. Because the review was not assessing AE prevalence, studies still scored for a particular domain if no participants reported it, but the authors specified an intention to assess it (ie, included a scale with relevant items) and/or commented on its absence.
Assessment of Global Impact
In addition to quantifying AEs, clinical utility is enhanced if research addresses the broader impact of antipsychotic consumption on patient well-being. Studies that did not assess this, provided generalised anecdotal statements (eg, "side effects were mostly mild and transient"), or only addressed impact of preselected effects, such as EPS, were coded 0. Studies that quantified responses using nonstandardized questionnaires (eg, authors' own Timeframe Short-term assessment cannot provide comprehensive data on AEs with long induction periods (eg, weight gain, sexual dysfunctions, amenorrhoea, tardive dyskinesia). Assessment length was therefore coded as: 0, 12 weeks or less; 1, 13 to 24 weeks; 2, 25 weeks or longer. If treatment duration was not provided, then timeframe was coded according to the length of the study. For cross-sectional studies, coding was organized according to whether authors reported mean treatment duration.
Sample Size
Larger samples have greater representation, as well as permitting identification of less common effects. Because no clear guidelines exist for determining adequate population size for antipsychotic AEs, studies were partitioned and coded according to the second, third, and fourth percentiles of the entire sample: 0, 76 or less (49.2%; n = 189); 1, 77 (26.3%; n = 101); 2, 225 or less (24.2%; n = 93).
Conflict of Interest
Research subsidised by pharmaceutical companies has been shown to be more likely to support industry interests, 31, 32 including incomplete or inconsistent AE reporting, 33 or reporting more favourable AE results for the sponsor's product relative to independent trials. 34 Studies receiving industry funding, or in which authors declared receipt of honoraria from drug companies, were therefore coded with 0. Those with no reported affiliation were coded with 1.
Global Comprehensiveness Score
This was calculated by summing scores for each AE domain (0-18), global impact (0-2), timeframe (0-2), sample size (0-2), and conflict of interest (0-1), resulting in a maximum possible score of 25 (see Table 2 ).
Analysis
Variables related to study characteristics and comprehensiveness criteria were summarized using descriptive statistics. Nonparametric analyses (between-group comparisons for the assessment of AEs, global impact, and declared conflict of interest) were performed with the Kruskall-Wallis H test, Dunn multiple comparison post hoc test, and Friedman 2-way analysis of variance by ranks. Parametric analyses (timeframe, global comprehensiveness scores) were conducted using 1-way analysis of variance procedures and the Tamhane T2 post hoc comparison. Associations between variables were computed with Spearman rank correlation coefficient. All analyses used SPSS Statistics v.21.0 software.
Reliability Checking
Data were extracted and coded by the first author and entered into an electronic data collection form, which was subsequently rechecked for missing or incorrect entries. Data deemed ambiguous were discussed and categorised in consultation with the second author, with any discrepancies resolved by consensus. Rating was not blinded to author or results.
As a reliability measure, 16 articles were randomly selected and coded by an independent rater. Values were compared and inter-rater reliability calculated using Cohen κ. Of the 13 categories, 7 showed 100% agreement, five 93.8% agreement (κ = 0.88), and one 87.5% agreement (κ = 0.76). Using Landis and Koch's 35 guidelines, in which a κ value greater than 0.70 suggests strong concordance, all variables indicated good reliability.
RESULTS
Of the recovered publications, 819 fulfilled criteria on the basis of title and abstract review and were retrieved to assess inclusion eligibility. Three articles could not be located. Of the remaining papers, 384 met criteria and were retained for review. These were subsequently organized according to four research designs: retrospective observational (n = 40), prospective observational (n = 50), cross-sectional (n = 67), and clinical intervention (n = 227).
Sample characteristics are presented in Table 2 . The most common population was psychosis patients (222; 57.8%), followed by developmental disorders (30; 7.8%) and bipolar disorder (25; 6.5%). The majority of studies recruited adults (259; 67.45%), with a smaller number reporting results from child/adolescent samples (66; 17.2%), elderly participants (32; 8.3%), or mixed age groups (27; 7.0%). Medication dosage was reported in 331 studies (86.2%) and polypharmacy in 323 (84.1%).
Assessment of Adverse Effects
The review identified 37 instruments for assessing AEs. Table 3 presents the 10 most commonly used. Figure 1 displays the percentage of studies from each design reporting on different AEs and Figure 2 presents the percentage of studies across the whole sample using informal or standardized measures for each AE category.
EPS were the most consistently assessed and reported in the sense they were most likely to be referred to, and more likely to be assessed using validated scales. This was closely followed by cognitive effects, although in many cases this was limited to only sedation/fatigue. When frequencies were recalculated to determine the proportion of studies reporting at least 1 nonsedative cognitive effect using either standardized or informal measures there was a noticeable decrease: 10 retrospective observational studies (25.0%), 38 prospective observational (76.0%), 50 crosssectional studies (74.6%), and 134 clinical studies (59.0%). As a weighted mean percentage across all four designs, this translated to a decrease from 90.7% to 60.4%. Of the remaining categories, metabolic and autonomic effects were reported in around two thirds of papers. Approximately half reported miscellaneous "other," anticholinergic, and hormonal effects. Affective and cutaneous effects had the poorest measurement, being assessed or reported in less than a third of cases.
The 0 to 2 coding frame was used to calculate a mean rank score of methodological rigor for each AE category. Results were: EPS (7.15), metabolic (6.47), cognitive (6.14), autonomic (5.17), anticholinergic (4.57), 'other' (4.69), hormonal (4.12), affective (3.48), and cutaneous (3.20) . Comparisons, using Friedman 2-way analysis of variance, indicated that EPS scored significantly higher than all other categories (all P's = 0.001). There was no significant difference between metabolic and cognitive effects, or affective and cutaneous effects (all P's = 1.00). Hormonal effects did not differ significantly from anticholinergic or "other" effects, and anticholinergic effects did not differ significantly from "other" or autonomic effects (all P's ≥ 0.086). Each of the remaining pairwise comparisons were significant (all P's = 0.001). When examining mean ranks for AEs according to study design, the Kruskal-Wallis H statistic was not significant for autonomic effects, or "other" miscellaneous effects (all P's ≥ 0.117). Of the remaining effects, post hoc comparisons indicated that EPS were best assessed in clinical and cross-sectional designs (all P's = 0.001), and metabolic effects were best assessed in clinical studies and observational prospective designs (all P's = 0.001). Cutaneous (all P's ≤ 0.02) and anticholinergic effects (all P's ≤ 0.034) were best assessed in cross-sectional studies. Cognitive, affective, and hormonal effects had the best assessment in both crosssectional and observational prospective designs (all P's ≤ 0.024). Table 4 presents the measures identified in the review for assessing global impact of antipsychotic use. This was poorly addressed across the literature, with only 59 studies (15.4%) using a validated instrument to report patient experiences. Of these, 7 did not use the scales presented in Table 4 but calculated associations between AEs and standardized outcomes, such as the Quality of Life Enjoyment and Satisfaction Questionnaire. A further 75 (19.5%) did not use validated measures, but quantified AE impact with more informal criteria (eg, mild/moderate/severe ratings).
Assessment of Global Impact
The study designs significantly differed in assessment of global impact (χ 2 (3) = 121.83, P = 0.001). Post hoc comparisons indicated that mean rank scores for cross-sectional studies were significantly higher than the other 3 designs (all P's = 0.001), with observational prospective studies scoring higher than observational retrospective and clinical studies (P = 0.001). There was no significant difference between observational retrospective and clinical studies (P = 0.27).
Withdrawal From Clinical Studies
Data were additionally extracted for the number of clinical studies reporting how many participants withdrew because of AEs. Across the sample, only 20 (8.8%) did not address the issue of drug tolerability on discontinuation rates. Of the remaining 207, 50 (22.02%) reported no dropouts; 80 (38.6%) provided the number of withdrawals; and 73 (35.3%) reported the numbers 
Timeframe
Across the entire sample, the mean (SD) timeframe for antipsychotic usage was 40.7 weeks (90.6). Cross-sectional studies had the highest mean timeframe at 104.2 weeks (171.1), followed by prospective observational studies at 63.7 weeks (115.2), retrospective observational at 58.7 weeks (83.6), and clinical studies at 23.1 weeks (55.3). This distribution was significantly different across study designs (F(3) = 11.10; P = 0.001). Post hoc tests indicated that clinical studies reported significantly shorter durations than cross-sectional studies (P = 0.045). No other pairwise comparisons showed significant differences. It should also be noted that the cross-sectional studies had a large amount of missing or unusable data (46.3%; 31/67). This was due to authors either not specifying the duration of participants' antipsychotic use, or reporting a broad range without providing a mean figure.
Sample Size
Across all studies, the mean (SD) sample size was 576.2 (3336.6). Mean sample sizes according to study design are presented in Table 2 , of which the largest was prospective observational studies, followed by retrospective observational studies, cross-sectional studies, and clinical studies. Although there was significant variation across the sample (F(3) = 7.4; P = 0.001), post hoc tests did not reveal any differences between designs (all P's ≥ 0.23).
Conflict of Interest
The design with the greatest frequency of drug company affiliations were clinical studies (70.0%; 159/227), followed by prospective observational (38.0%; 19/50), cross-sectional (23.9%; 16/67), and retrospective observational (17.5%; 7/40). This difference in distribution was significant (χ 2 (3) = 73.67, P = 0.001), with clinical studies reporting significantly more conflicts of interest than each of the other three designs (all P's = 0.001). No other pairwise comparisons were significant.
Global Comprehensiveness Rating
There was a weak positive association between publication date and total comprehensiveness score across the entire sample, indicating that AE assessment and reporting has improved marginally over time (r s = 0.18, P = 0.001).
There was a significant difference in scores across the 4 study designs (F(3) = 27.39; P = 0.001). Post hoc tests indicated no differences between cross-sectional and prospective observational studies (P = 0.08). However, both these designs scored significantly higher than clinical studies and retrospective observational studies (all Ps ≤ 0.01). In turn, clinical studies scored significantly higher than retrospective observational research (P = 0.001).
A post hoc analysis was also performed to examine comprehensiveness score according to sample age group: adults aged 66 years or older (n = 32), adults aged 18 to 65 years (n = 259), and children/adolescents aged 17 years or younger (n = 66). Twenty-seven studies were excluded from this analysis, either because mean age was not provided (n = 11) or because the authors had recruited mixed samples of children/adolescents and adults (n = 16). There was a significant difference across the sample (F(2) = 218.70; P = 0.001). The mean (SD) score of 6.88 (3.07) for elderly adults was significantly lower than the mean of 10.77 (4.57) for adults aged 18 to 65 years, or the mean of 10.02 years (3.67) for child/adolescent samples (all P's = 0.001). There was no significant difference between adult and child/ adolescent samples (P = 0.41).
DISCUSSION
Accurate detection, classification, and management of AEs are important from both clinical and research stances. This review systematically examined strategies used to record and report antipsychotic AEs, and assessed the clarity and comprehensiveness of these. First, the results demonstrate that neurological, metabolic, and sedation-related cognitive effects are most consistently assessed and reported across the literature. Second, the global impact of antipsychotics on patient well-being was poorly assessed. Finally, the cross-sectional and prospective research designs yielded the most comprehensive AE data.
Assessment of Adverse Effects
The current findings are similar to Pope et al 22 whose review of 167 antipsychotic trials likewise found that EPS were assessed more frequently and systematically than other AEs. Given their debilitating and potentially irreversible nature, it is encouraging that motor disturbances were carefully reported across different designs. Nevertheless, the reduced risk of EPS associated with atypical antipsychotics means privileging their assessment over other effects may no longer be clinically justified. This inconsistent assessment of nonneurological effects replicates the conclusions of existing surveys, 22,49,50 despite concerns about the substantial impact of non-neurological AEs on factors like physical attractiveness, 51 feelings of reduced intelligence and creativity, 52 and social stigma and ridicule. 53 Furthermore, although sedation was generally well reported, affective and nonsedative cognitive AEs were referred to far less frequently, despite patient testimony that subjective effects like dysphoria (eg, feeling "robotic," "emotionally empty," 52 ) are both common and distressing.
In addition to the types of AEs reported, limitations were also apparent in their assessment. An exception to this was EPS. For example, a review of 2000 intervention studies between 1950 and 1998, 59% of which were for antipsychotics, 54 found only 17% used either the SAS, AIMS, or ESRS to assess neurological AEs. The current findings indicate a welcome reverse in this trend. However, non-neurological AEs were much less likely to be assessed with validated measures. This is important because solicited, systematic inquiry using structured checklists is more likely to provide comprehensive data than open-ended questioning, which in turn is more efficient than spontaneous/voluntary reporting. Although the latter has the advantage of simplifying research protocols by reducing the number of formal measures participants 56, 57 Neither is this limited to severe effects, with the detection of mild to moderate problems necessitating a change in clinical management improving by approximately 40% using systematic check-
lists compared with open-ended inquiry. 58 It is important that research inconsistencies do not translate into mistaken assumptions about prevalence in clinical practice, and the privileging (for example) of enquiries about EPS, weight gain, and sedation over other domains. For example, although affective and cutaneous effects were infrequently assessed or reported across the sample, these experiences have prevalence rates of between 38.4% and 66.0% (emotional) and 29.2% and 50.0% (cutaneous). [59] [60] [61] [62] Similarly, a probability sample of 243 patients found higher rates of emotional (18.8%) and cutaneous (17.3%) effects than EPS, such as body rigidity (11.4%) and tardive dyskinesia (7.6%; although not akathisia: 27.1%). 63 Further limitations in reporting and interpretation of AE data reflected those previously observed in existing reviews of antipsychotic trials 22,64-66 as well as other medical disciplines. 20, 21 These included timeframes that were insufficient to detect AEs with long induction periods, inadequate detail about AE frequency/ duration, reporting aggregated subscale scores from different measures rather than specifying individual effects, not reporting numericized results of Likert-scale severity measures and/or using ambiguous severity summaries (eg, "the majority of patients were not troubled by AEs"; "AEs were mild and transient") without providing operational definitions of what these terms imply. Inconsistent terminology and classification was also evident (eg, "agitation" without denoting cognitive AEs, psychiatric distress, or the neurological impact of akathisia; differentially classifying seizures as a form of EPS, an autonomic effect, or an unspecified "other" effect). In this respect, The Coding Symbols for Thesaurus of Adverse Reaction Terms 67 was instigated to support standardized and consistent reporting. However, of the 362 papers in the review published from 1991, only 19 referred to these guidelines. Only 3 cited the more recent Medical Dictionary for Regulatory Activities 68 terminology.
Specific limitations in the design of clinical studies included the use of first-generation agents as comparators (which is likely to inflate EPS incidence data), only reporting AEs noted in at least 10% of patients or those that significantly differed between test and comparator drugs, not providing follow-up on withdrawn participants, and not clearly specifying whether cognitive/affective changes were the results of medication or underlying psychiatric states. Carry-over effects were also inconsistently addressed (eg, if patients have gained weight from prior medication, weight gain may be underestimated as the potential for further increase is limited 69 ). There was also a tendency to report AEs in ways which have negligible clinical meaning: for example, reporting samplewide mean changes in weight, EPS scales, and plasma prolactin elevation as opposed to the absolute proportions of participants gaining weight, the number of patients reaching diagnostic threshold for movement disorders, or those exhibiting hyperprolactinaemia.
Assessment of Global Impact
Withdrawal rates due to AEs were reported consistently among the clinical studies, although there was negligible transparency about the types of effects precipitating dropout. Although separate reporting of tolerability and efficacy as reasons for premature discontinuation is encouraging, this failure to specify the AEs impairs the consistency and expediency of the measure, particularly if efficacy-related events (eg, worsening of psychosis) are included in the AE category. 66 Furthermore, most studies prioritized quantifying AEs over establishing their subjective impact. Even with our lenient criteria (eg, coding for Likertstyle mild/moderate/severe indicators), only 34.9% of studies scored on this measure. Validated scales assessing subjective tolerability were particularly poorly used, being reported in only 15.6% of cases. This absence is of special concern, given that subjective well-being on antipsychotics is identified as a major component by the Remission in Schizophrenia Working Group. 70 Distress from AEs "is a moving target, affected by social expectations, knowledge, and alternative choices" wherein objective measures of particular effects will not inevitably correlate with subjective impact (Rabkin et al, p.46). 58 For example, distress may fluctuate according to the respite drugs provided from symptoms. 71 Other variables influencing treatment satisfaction can include the quality of the therapeutic alliance, 72 shared decisionmaking in care planning, 73 and frequency of hospital admissions. 74 Additional variations may be sex-specific, with women more likely to be distressed by weight gain and men more likely to experience distress over sexual dysfunction. 75 Taken together, the current results emphasize the importance of more proactive strategies for assessing the impact of antipsychotic consumption. For example, Naber 13 conceptualizes the global effects of antipsychotics within a 5-factor model of mental functioning, physical functioning, emotional regulation, self-control, and social integration; subsequently expanded to include the influencing factors of psychopathology and symptomatic improvement, psychosocial factors, phase and severity of illness, attitudes toward pharmacological treatment and insight, and physical AEs and associated distress. 76 Studies operationalizing these constructs with the SWN 13 scale report significant associations with drug compliance, 13, 77 with stronger correlations between SWN factors and depression and anxiety than SWN factors and psychotic symptoms themselves. 44 Our finding that AE assessment and reporting was significantly less rigorous in elderly populations additionally highlights the need for increased vigilance among patients for whom experiences like dementia and negative symptoms makes spontaneous reporting of distress more problematic. In summary, AEs should not be minimized as an inevitable penalty of successful treatment. Vigilant approaches to detection can facilitate prompt identification of difficulties, instigation of interventions to minimise patient burden, and ultimately reduce the likelihood that therapeutic impact becomes overridden by AEs.
Research Designs
Levine 78 defines 3 methodological considerations for improving AE data: assessment method, timeframe, and whether information permits judgments about cause and extent of clinical impact. This closely corresponds to our own aggregated coding for comprehensiveness, on which basis prospective observational and cross-sectional designs emerged as the most comprehensive data sources. This was particularly owing to their larger sample sizes, greater use of standardized assessment, and consideration of both global drug impact and long-term antipsychotic use. Notwithstanding the considerable advantages of clinical trials for minimizing bias and confounding, and for generating valuable data against placebo or comparator drugs, we found that AE reporting was often limited by small samples, short assessment durations with limited generalizability, an over-reliance on spontaneous self-report data, and the tendency to emphasize efficacy and symptom control over tolerability. Retrospective studies (which in the current review mostly encompassed medical note audits) can in turn generate insights into large samples of "real-world" patients and practice while remaining limited by unsystematic assessment and incomplete data. Nevertheless, it is also important to acknowledge that all research designs carry relative strengths and limitations, and that the most comprehensive insights into AEs can probably be reached by considering heterogeneous evidence sources together. 64 For example, cross-sectional studies are less likely to define the nature of the intervention and have fewer contingencies to control confounding. Similarly, despite the limitations of spontaneous self-report, this method has a capacity to elicit rare or unexpected effects that is prohibited with standardized scales. Nevertheless, our findings suggest that the despite the primacy placed on clinical trials, observational studies are also a useful source of data for policy makers, clinicians, and researchers seeking to understand AE prevalence and impact.
Limitations
The intention of this review was to characterize recurring themes and limitations in the antipsychotic literature. In this regard, its main strength-a comparatively large, representative sample-was also the source of its main limitations. The inclusion of so many publications necessitated summarizing a sizeable literature via broad conclusions. Some nuances of individual studies were not captured. Furthermore, our review was not preregistered.
Our AE coding may have reduced discriminative capacity by subsuming diverse experiences under a single domain (eg, sexual dysfunctions, menstrual irregularities, and gynecomastia were all categorized as "hormonal"). Similarly, inconsistent classification in the sampled studies meant reported results did not always correspond with our categories. For example, some authors used "other effects" to refer to all non-neurological AEs. For subjective psychological effects, it was not always clear to what extent these were the result of psychosis/psychosocial adversity rather than medication; as such the review may have overestimated assessment rates of cognitive and emotional AEs.
Search limitations may also have created bias. This includes our decision, because of the large size of the literature, to limit our search to a single database. Although our choice of PsycINFO increased the likelihood of detecting the type of observational, nonclinical studies in which we were interested, reliability would have been improved by including other databases. Similarly, the lack of double extraction procedures may have reduced the quality of our findings. The exclusion of non-English language journals further risked language bias. The latter may be particularly relevant, because cross-cultural disparities are apparent in AE identification 79 and reporting. 80, 81 Demonstrated inadequacies in the ways AE data are indexed in electronic databases 82 means relevant studies may have been missed. It is further possible that studies with low scores for AE assessment (eg, small samples and reliant on spontaneous self-report) simply reflected a genuine absence of particular effects. In this respect, the comprehensiveness scores were also subjectively operationalized. However, the high interrater reliability, as well as consistency of the results with both existing literature, and between and within the 4 study designs, suggests the findings retain reasonably strong validity.
